pulmatrix.com
Get leads like Pulmatrix — and thousands more
Build targeted lists by tech stack, traffic, and more
Pulmatrix: The $148M Bet on Inhaled Drug Delivery
A stealthy biotech with massive funding and a singular focus on pulmonary delivery.
In the high-stakes world of biotech, where billion-dollar bets are often placed on crowded therapeutic areas, Pulmatrix is taking a different route—literally. By leveraging its proprietary iSPERSE™ technology, this company is betting big on the lungs as the ultimate gateway for treating serious diseases, securing nearly $150M in funding to prove it.
"Pulmatrix isn't just building drugs; they're engineering a new delivery paradigm for the most challenging respiratory diseases."
The iSPERSE™ Advantage
At the core of Pulmatrix's strategy is iSPERSE™, a dry powder technology designed to overcome the limitations of traditional inhaled therapies. Unlike conventional methods that struggle with particle size and lung deposition, iSPERSE™ enables precise delivery of therapeutics directly to the pulmonary system. This isn't incremental innovation—it's a fundamental rethinking of how drugs enter the body for conditions like COPD, asthma, and rare lung diseases.
The Funding & Traffic Paradox
Here's the intriguing contradiction: Pulmatrix has raised $148.2M—a massive war chest for a 39-person team—yet its web presence is minimal with just 1,786 monthly visits. This suggests a highly focused, B2B-driven model where investor relations and pharmaceutical partnerships matter more than public traffic. The 46% direct traffic indicates a dedicated following, likely from investors and industry insiders tracking their progress.
The company's leadership team, led by CEO Ted Raad, brings deep pharmaceutical expertise. With a revenue of $7.5M, Pulmatrix is in that critical pre-commercialization phase where R&D spending dwarfs revenue—a classic biotech story. The fact that they're generating any revenue at this stage suggests early partnerships or milestone payments, a positive signal for investors.
- iSPERSE™ technology enables ultra-fine dry powder delivery with precise lung targeting
- Strategic focus on pulmonary-delivered therapeutics for serious diseases
- Strong financial backing ($148M) provides runway for clinical development
- Minimal public footprint suggests deep pharmaceutical industry relationships
The Silent Giant of Pulmonary Drug Delivery
With $148M in funding and proprietary tech, Pulmatrix is playing the long game in a niche where execution matters more than hype.
What tech stack does Pulmatrix use?
How much traffic does Pulmatrix get?
Traffic & Engagement
Traffic Sources
Where is Pulmatrix's audience located?
What keywords does Pulmatrix rank for?
5 keywordsHow is Pulmatrix's SEO?
Meta Tags
PULMATRiX
With iSPERSE ™ technology, PULMATRiX is expanding therapeutic care for patients with serious disease through a new generation of PULMONARY-DELIVERED THERAPEUTICS.
H1 Tags
What is Pulmatrix's revenue?
Who works at Pulmatrix?
Loading leads...
What do customers think of Pulmatrix?
No Trustpilot reviews available for this company.
Frequently Asked Questions about Pulmatrix
What is Pulmatrix's Revenue?
What does Pulmatrix do?
How fast is Pulmatrix growing?
What technologies does Pulmatrix use?
Who are Pulmatrix's competitors?
Export Data
Unlock all exports
Download CSVs, JSONs & full reports
How to contact Pulmatrix?
Social Profiles
Export pulmatrix.com Data
Download the complete tech stack, analytics, leads, and company data for pulmatrix.com in JSON or CSV format. Use it for your sales pipeline, competitive analysis, or research.
Raw JSON Data
Click "Show" to view the raw API response data
About pulmatrix.com
With iSPERSE ™ technology, PULMATRiX is expanding therapeutic care for patients with serious disease through a new generation of PULMONARY-DELIVERED THERAPEUTICS.
Company Overview
pulmatrix.com Social Media
Technology Stack
pulmatrix.com uses 5 technologies across their website including Google Fonts, DaisyUI, Bootstrap, Tailwind CSS, and more.
Fonts
Google Fonts
UI Libraries
DaisyUI
CSS Frameworks
Bootstrap, Tailwind CSS
JavaScript Libraries
jQuery
Traffic & Audience
pulmatrix.com receives approximately 1.8K monthly visitors and ranks #9,078,013 globally. The website has a bounce rate of 45% with visitors viewing an average of 1.6 pages per visit. Users spend an average of 0:19 on the site.
The majority of pulmatrix.com's traffic comes from undefined, .
Frequently Asked Questions
What is pulmatrix.com?
What technologies does pulmatrix.com use?
How do I contact pulmatrix.com?
What are pulmatrix.com's social media accounts?
Is pulmatrix.com hiring?
How popular is pulmatrix.com?
Related Searches
This page provides publicly available information about pulmatrix.com. Data is collected from various public sources and may not always be up to date. For the most accurate information, please visit pulmatrix.com directly at https://pulmatrix.com.